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 DM1 – Type 1 Diabetes 
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1. INTRODUCTION 
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1.1. Diabetes mellitus  
 
Millions of people in the United States are affected and have been diagnosed with 
diabetes mellitus (1). Of which, the two most common forms are type 1 diabetes (DM1) and 
type 2 diabetes (DM2). Type 1 diabetes is an autoimmune disease in which the pancreatic beta 
cells, which secretes insulin, are attacked and ultimately cause a decrease of circulating insulin 
(2). On the other hand, type 2 diabetes can be seen as a combination of pathophysiology in 
which there is both insulin resistance and insulin deficiency (3). The causes of DM 2 are 
multifactorial such as genetics and environmental factors. Environmental factors include, but 
not limited to: obesity, lack of exercise, stress, and aging (4). In terms of genetics, it is quite 
clear that past family history plays a role in the development of DM 2 (5).   
    
The pathophysiology of DM 2 that was previously mentioned is due to a mixture of 
insulin resistance and insulin deficiency. Insulin resistance is defined as insulins inability to 
produce its physiological actions on its target cells at normal circulating concentrations (6). 
This insulin resistance is largely in part of metabolic syndrome. Metabolic syndrome is plethora 
of pathophysiology which greatly increase the risk of cardiovascular disease, DM2 and all 
causes of mortality (7). One of the major complications of DM 2 is heart failure. 
 
1.2. Heart failure 
 
 Heart failure has been shown in clinical trials to have an increase prevalence in diabetic 
patients (8). Many of these diabetic patients do not have any history of other cardiac risk factors 
such as coronary heart disease, hypertension and significant valvular disease. Yet, there is still 
abnormal myocardial structure and performance in these aforementioned patients, and thus this 
phenomenon has been aptly named diabetic cardiomyopathy. Diabetic cardiomyopathy can be 
defined as the presences of an abnormal myocardial structure and performance in the absences 
of other cardiac risk factors which include but not limited to: coronary artery disease, 
hypertension and significant valvular disease, in individuals with diabetes mellitus. 
 
 The prevalence of heart failure in diabetic patients can range between 19 - 26% (9). The 
classic Framingham Heart Study showed that the incidence of heart failure was increased in 
both male and female diabetic patients in comparison with age-related individuals. This 
surprisingly was independent of obesity, hypertension, dyslipidemia and coronary heart 
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disease. Interestingly enough the incidence of heart failure was higher in diabetics as compared 
to nondiabetics. Further studies have shown that the differences in left ventricular mass and 
wall thickness and increased diastolic and systolic dysfunctions between diabetic patients and 
normal patients (10). 
 
1.3. Diabetic cardiomyopathy 
 
Some of the risk factors for diabetic cardiomyopathy are those seen in DM2 such as: 
hyperglycemia, systemic insulin resistance, and impaired cardiac metabolic signaling all of 
which are involved in the pathogenesis of diabetic cardiomyopathy (Figure 1). When looking 
at the earliest stages of diabetic cardiomyopathy many of the patients are asymptomatic, yet at 
this stage the heart is undergoing structural changes. This can be seen in changes in the left 
ventricle, in which it becomes hypertrophic and has a decrease compliance. These changes then 
cause: an impaired diastolic filling, increased atrial filling, and a prolong isovolumic relaxation 
(11).  
It is important to note that patients start showing symptomatic heart failure once there 
has been there is impaired systolic function (12). On the molecular level, these structural 
changes are largely due to the impaired insulin metabolism. This impairment causes a decrease 
amount of glucose transporter 4 (GLUT4) on the target cells plasma membrane. When this 
occurs, a cascade of events will begin (13). 
These events will result with glucose not being able to enter a targeted cell, in turn 
causing sarcoplasmic Ca2+ pump activity, which then allows an increase amount of Ca2+ 
intracellularly in a cardiomyocyte. Ultimately, this will case cardiomyocyte stiffness. Another 
abnormality due to impaired insulin metabolism is a decrease in insulin-stimulated coronary 
endothelial nitric oxide synthase activity (eNOS). The reduction of nitric oxide, known for its 
vasodilatatory effects, causes titin to stiffen and thus also causes cardiomyocyte stiffness. 
These structural abnormalities such as the aforementioned cardiac stiffness and impaired 
relaxation are the hallmark pathological changes of a diabetic heart (14). 
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Figure 1. Pathophysiological mechanisms of diabetic cardiomyopathy (8) 
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1.4. Cardiac Metabolism 
 
In diabetic patients one can notice the change of cardiac metabolism. In order to 
understand the complexities of the cardiac energy metabolism, one must understand the cellular 
standpoint of the creation of energy. ATP generation of the heart is largely due to oxidative 
phosphorylation (Figure 2) of a cardiomyocyte mitochondria (15). In a healthy heart, oxidative 
phosphorylation is uniquely correlated with ATP hydrolysis. In other words, the more ATP 
that is broken down, the more active oxidative phosphorylation becomes thus the allowing 
proper cardiac contractility.  
 
 
 
Figure 2. The pathways for and regulations myocardial substrate metabolism (15) 
 
 
This allows the ATP storage constant even in times of increase cardiac energy usage 
such as exercise. The cardiomyocyte mitochondria oxidative phosphorylation is driven by 
electron transport of carbon which is ultimately due to the presences of reduced form of 
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nicotinamide adenine dinucleotide (NADH) and reduced form of flavin adenine dinucleotide 
(FADH2) which are products of beta oxidation of free fatty acids (16). 
 
1.5. Beta oxidation of free fatty acids 
 
Beta oxidation of free fatty acids is a pinnacle in terms of cardiac metabolism and 
energy creation. The products that are created such as NADH, FADH2, and acetyl-CoA. But, 
before beta oxidation in the mitochondria can occur, a precursor of acetyl-CoA, long-chain 
acyl-CoA, must go through changes in the cytosol before entering the mitochondria. Once it 
becomes its “proper” form to speak, beta oxidation can occur. The process of beta oxidation is 
a continuous cleaving mechanism that takes away two- carbon acetyl-CoA. Certain enzymes 
are need to cleave off certain lengths of fatty acid intermediates, but the end result is the much 
needed NADH, and FADH2 (17). 
 
1.6. Cardiac metabolism for carbohydrates 
 
 Cardiac metabolism can also be dependent on carbohydrates. The glycolytic pathway 
is driven from exogenous glucose and glycogen storage. For every glucose molecule a net of 2 
ATP is created. The transport of a glucose molecule into a cardiomyocyte is regulated by not 
only a glucose gradient, but also due to the content of the glucose transporter (18). In this case, 
the transporter is mainly GLUT-4. The glycolytic pathway has enzymes that help regulate its 
forward movement. One of which is phosphofructokinase-1 (PFK-1). This enzyme is pertinent 
regulator and the first irreversible step in the glycolytic pathway.  Without this enzyme the 
glycolytic pathway cannot move forward. Another key substrate created in this process is 
pyruvate (19). 
Pyruvate has three main outcomes in terms of metabolism: help create pyruvate, 
decarboxylation to Acetyl-CoA, or carboxylation to oxalate or malate (20).  The oxidation of 
glucose and pyruvate in conjunction with the activity of PDH are decreased when the rates of 
fatty acid oxidation are increased. Furthermore, the activity of pyruvate oxidation is enhanced 
by the decrease activity of free fatty acid oxidation (21). As one can see there is a continuing 
checks and balance between the two-metabolism cycle.  
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1.7. Changes in metabolic cycles in heart failure 
 
 The aforementioned metabolism cycles are changed in terms of heart failure. Though 
the actual causes and consequences of these abnormalities are not well documented. There is 
however some evidence that shows that these changes in the metabolism contributes towards 
the contractile dysfunction and to a chance in the left ventricular remodeling that are 
characteristic of heart failure (11).  The idea behind this is the notion that myocardial substrate 
selection is somewhat normal during the beginning stages of heart failure. Eventually in the 
advanced stages there is a notable change in the downregulation in the fatty acid oxidation, an 
increased glycolysis and glucose oxidation, reduced respiratory chain activity and impaired 
reserve for mitochondrial oxidative flux (22). 
The reducing equivalents generated from the intermediary metabolism is electron 
transport chain and oxidative phosphorylation. In heart failure there is a defect in the transfer 
of energy from mitochondrial ATP to the site of ATP hydrolysis and the use of the creatine 
phosphate system. There seems to be a decrease in tissue ATP content, a rise in ADP, and a 
decrease in the phosphorylation potential. This ultimately impairs the kinetics for ATP use for 
cell contraction and relaxation. Furthermore, heart failure hinders the potential for the creatine 
kinase system to transfer for mitochondrial ATP to myofibril (23). 
A dysfunctional electron transport chain can also affect the mitochondrial and cytosolic 
redox state (NADH/NAD+) and the pool of ATP, ADP, and Pi. When looking at the 
mitochondria of a failing heart there is a noticeable difference in membrane disruption and 
matrix depletion, a lower use for respiration, and decrease capacity for oxidative 
phosphorylation. (24).  The activity of the complex III was reduced by 35% with no changes 
in the other complexes in patients with either idiopathic dilated cardiomyopathy or a previous 
histories of ischemic heart disease compared with donor hearts with normal cardiac function 
(25).  This shows that in heart failure there is a major disruption in oxidative metabolism at the 
level of the electron transport system. 
 
 Unfortunately, there is not that much data of the effects of heart failure on myocardial 
substrate oxidation in patients with heart failure. The few data that has been obtain shows that 
in the early stages of heart failure, there is a slightly elevated rate of fatty acid oxidation. In 
one particular study (26), there is an increased uptake of plasma free fatty acid and a decrease 
in uptake in congestive heart patients. Now, if we combine that with a diabetic heart this can 
only further the demise of the patient.  The purpose of this study is to find out what the direct 
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cause of diabetes in heart failure in terms of a dysfunctional myocardial substrate metabolism 
and fuel selection.  
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2. OBJECTIVES 
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The main goal of the present study was to investigate directly the ability of heart mitochondria 
to metabolize fatty acids and carbohydrates in patients suffering from DM2. Since DM2 is a 
metabolic disease which disturbs normal metabolic processes in the entire body, we wanted to 
explore the potential impact on utilization of the main substrates in metabolically very active 
organ, such as heart. Although some studies had been performed in animal models of diabetes, 
investigation conducted on the tissue derived from human DM2 patients enables a direct insight 
into clinically relevant aspects of the disease.  
 
Hypothesis 
The main hypothesis of our investigation is that left ventricular mitochondria from patients 
suffering from DM2 will exhibit reduced capacity for oxidation of fatty acid. 
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3. SUBJECTS AND METHODS 
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3.1. Study design 
 
In this study, we included thirty-seven patients who had been previously diagnosed with 
coronary artery disease (CAD), were hemodynamically stable and were scheduled for elective 
coronary artery bypass grafting (CABG) surgery. Emergency patients, patients with LV 
ejection fraction (LVEF) below 50%, patients with type 1 diabetes mellitus, concomitant valve 
replacement, and severe renal, hepatic or pulmonary disease were excluded from our 
investigation.  
Furthermore, the included patients were subdivided into two categories. One group of 
nondiabetic patients (labelled as nonDM group) and the second the diabetic group (labelled 
DM). The diabetic group were patients defined on the clinical diagnosis of Type 2 Diabetes 
(DM2), chronic use of diabetic medication, having a fasting plasma glucose (> 7 mml/L) or a 
glycosylated hemoglobin (HbA1c >6.5%).  Pre-, intra- and post-surgical procedures were 
performed according to the standard clinical routines of the Department of Cardiac Surgery at 
the University Hospital of Split. This experiment and all subsequent processes follow the 
Declaration of Helsinki and was approved by the Ethical Committees of the University Hospital 
of Split (2181-147-01). All patients were explained the planned procedures and study 
objectives in detail prior to giving the signed informed consent for their enrollment.  
 
3.2. Left ventricular biopsies 
 
Biopsy samples were obtained during the CABG procedure that was performed without 
the use of cardiopulmonary bypass and cardioplegia (“off-pump”). One cylinder-shaped 
sample (approximately 15 x 1 mm) was taken from the anteroseptal part of the left ventricle 
from each patient. No complications evidently related to the biopsy procedure was detected in 
any of the patients. Upon the biopsy, the sample was immediately immersed in an ice-cold 
storage solution, composed of 2.77 mmol/l CaK2EGTA, 7.23 mmol/l K2EGTA, 6.56 mmol/l 
MgCl2, 5.7 mmol/l Na2ATP, 15 mmol/l phosphocreatine, 20 mmol/l imidazole, 20 mmol/l 
taurine, 0.5 mmol/l dithiothreitol and 50 mmol/l K-methanesulfonate, pH 7.1 at 0°C. 
Afterwards, the samples were transferred within 15 minutes to the Laboratory of Cellular 
Physiology at the Medical School in Split for the purpose of performing the in vitro 
experiments. 
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3.3. Chemicals 
 
All chemicals used for this study, unless otherwise noted, were purchased from Sigma-
Aldrich (St Louis, MO, USA).  
 
3.4. Mitochondrial respiration 
 
Upon arrival to the Laboratory, the samples were first inspected under a magnifier and 
cleaned from excess fat and fibrous tissues. Afterwards, they were fine dissected using a pair 
of extra-fine scissors in order to mechanically separate bunches of myocardial fibers allow for 
better access of a permeabilizing agent. For the permeabilization purpose, a mild detergent 
saponin was used (50 µg/ml), which was added to the storage solution and in which the tissue 
was incubated for 30 min at 4 degrees Celsius with mild agitation. Saponin is used because it 
acts primarily on cholesterol-containing membranes – such as plasma membrane, but not 
mitochondrial membrane which contains minimal amounts of this sterol. This allows for 
selective permeabilization of the cellular membrane and generation of the so-called skinned 
fibers. Such samples can be used for measurement of mitochondrial respiration, since due to 
the plasmalemma permeabilization there is an easy access of substrate to the mitochondria, 
which remain intact after the described procedure. 
Upon permeabilization, the samples were washed from the components of the storage 
solution by mild agitation at 4 degrees Celsius in the respiration buffer, that is composed of 
2.77 mmol/l CaK2EGTA, 7.23 mmol/l K2EGTA, 1.38 mmol/l MgCl2, 3 mmol/l K2HPO4, 20 
mmol/l imidazole, 20 mmol/l taurine, 0.5 mmol/l DTT, 90 mmol/l K-methanesulfonate, 10 
mmol/l Na-methanesulfonate, 2 mg/ml BSA, pH 7.1). Upon washing, the samples were 
transferred to the metabolic chamber that was filled with 2 ml of the respiration buffer, under 
constant stirring. After the skinned fiber is placed into the chamber, the lid is closed and the 
oxygen amount in the chamber is constantly monitored using an oxygen-sensing Clark-type 
electrode (Oxygraph, Hansatech Instruments, Norfolk, UK). During the experiment, as 
mitochondria respire, the oxygen level in the chamber decreases, which is recorded by a 
specially designed software. The rate of oxygen decline in the chamber is later calculated and 
it is indicative of the rate of mitochondrial respiration, or in other words of mitochondrial 
ability to oxidize the substrate. For the latter, either fatty acids or carbohydrates may be used, 
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which enables the researcher to assess the mitochondrial capacity to utilize either type of 
metabolite.  
 
3.5. Experimental Protocol 
 
In order to evaluate the capacity of cardiac mitochondria to metabolize fatty acid, we 
used palmitoyl-carnitine was used as a substrate (40 µmol/l) in the metabolic chamber. 
Palmitate is the most commonly used fatty acid in cardiac metabolism. With the chemical 
formula CH3(CH2)14COOH it is categorized as a long fatty acid and in order to enter the 
mitochondrial matrix, where it is further metabolized in a series of enzymatic events named  -
oxidation it needs to be conjugated to carnitine. In order to facilitate its entry into the 
mitochondria of the skinned fibers and eliminate the potential impact of the conjugation 
process, which may be dysfunctional in some patients, we used palmitoyl-carnitine in our 
system, which allowed a rapid delivery of a metabolite to mitochondria and investigation of 
the processes downstream. After palmitoyl-carnitine, we added ADP (2.5 mmol/l), in order to 
reconstitute mitochondrial respiration in vitro.  
High energy electrons, derived from the fatty acid, are shuttled to oxygen molecule via 
the mitochondrial electron transfer chain, with energy being transferred first into the proton 
gradient across the inner mitochondrial membrane and ultimately harvested in the form of ATP 
synthesis via the enzyme ATP synthase. Finally, we administered a chemical named 
trifluorocarbonylcyanide phenylhydrazone (FCCP, 1 µmol/l), which is an uncoupler of 
mitochondrial oxygen consumption from ATP synthesis. This yields even higher rates of O2 
consumption in mitochondria, enabling the evaluation of the full capacity of a certain metabolic 
pathway. 
In parallel, cardiac mitochondrial ability to metabolize carbohydrate was investigated 
by adding pyruvate (5 mmol/l) in place of palmitoyl-carnitine. Pyruvate is the main substrate 
of carbohydrate metabolism as it is derived from glucose via the glycolysis, which takes place 
in the cytosol. The example of the actual recordings evaluating the mitochondrial ability to 
oxidize palmitoyl-carnitine in the presence of ADP and FCCP is displayed in Figure A. As can 
also be seen in the figure, the level of available ambient oxygen was maintained above 210 
µmol/l to avoid its diffusion limitation in the fibers (reoxygenation of the system performed 
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before addition of FCCP). Myocardial oxygen consumption rate was expressed in pmolO2/s 
per milligram of wet tissue weight (ww). 
 
3.6. Statistical analysis 
 
Normality of distribution was checked using D’Agostino-Pearson test and, in case of 
normal distribution, unpaired Student t test was conducted for comparison. Data in figures are 
presented as means ± SEM. Correlation analysis was performed using GraphPad Prism 6 
software (San Diego, Ca, USA), with a two-sided p value < 0.05 considered as significant. 
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4. RESULTS 
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Examination of mitochondrial oxidation of the main energy substrates revealed 
significant alterations in the ability to process fatty acid in DM heart. Upon addition of 
palmitoyl-carnitine, respiration in the presence of ADP was significantly lower in LV 
myocardium from DM patients as compared to nonDM (Figure 3). The same effect was 
observed, albeit at the higher rates of oxygen consumption, upon addition of an uncoupling 
agent FCCP. On the other hand, ADP-supported mitochondrial oxidation of pyruvate, the 
specific substrate of carbohydrate metabolism, was not different between nonDM and DM 
group (Figure 4). Administration of FCCP accelerated the respiration in both groups to the 
same extent, suggesting that maximal electron transfer chain capacity is comparable between 
them. RCR values for palmitoyl- and pyruvate-fueled respiration also did not differ between 
nonDM and DM groups (Figure 5). Enzymatic activity of citrate synthase, a marker of 
mitochondrial content in the tissue, was not different between the two groups, indicating that 
the observed difference in mitochondrial palmitoyl oxidation is not due to decreased 
mitochondrial content in DM myocardium (not shown). 
The rate of mitochondrial respiration driven by palmitoyl-carnitine was negatively 
correlated with blood levels of HbA1c (r2=0.21) (Figure 6).  
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Figure 3. Oxygen Consumption Rate (OCR) for fatty acid oxidation is reduced in diabetic 
myocardium     
*P<0.05 versus nonDM group Oxygen 
 
Figure 4. Oxygen Consumption Rate for carbohydrate oxidation is unaltered in diabetic 
myocardium 
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Figure 5. Respiratory Control Ratio (RCR) values for palmitoyl- and pyruvate-fueled 
respiration 
 
 
 
 
Figure 6. Rate of mitochondrial respiration driven by palmitoyl-carnitine has a negative 
correlation 
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5. DISCUSSION 
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 To our knowledge, the current study represents the first direct assessment of the 
influence of type 2 diabetes mellitus on mitochondrial function in left ventricular myocardium 
of patients suffering from this condition, who have preserved cardiac contractile function. We 
found that the hearts of DM2 patients, even in the absence of contractile failure, a decreased 
mitochondrial capacity for oxidation of fatty acids and unchanged mitochondrial oxidative 
capacity for carbohydrates. 
Mitochondrial substrate oxidation capacity in diabetic LV myocardium. Essentially, a 
disease of energy metabolism, diabetes mellitus causes significant alterations of myocardial 
metabolism of carbohydrates and fatty acids. Due to insulin resistance, there is an increased 
lipolysis in adipose tissue, with increased fatty acid delivery to the myocardium (16). This is 
coupled with decreased insulin-stimulated GLUT-4-mediated entry of glucose into the cardiac 
myocytes.  
As a result, there is a change occurring in utilization of substrates, with augmented 
myocardial reliance on fatty acid uptake and metabolism for production of high-energy 
compounds and concomitantly decreased utilization of glucose. Most of the studies which 
investigated substrate utilization in patients with DM2 were performed at the level of whole 
heart, using positron emission tomography (PET), and were thus influenced by many variables, 
including plasma concentration of substrates.  
 In the current study, we investigated how ventricular mitochondria from diabetic 
patients process fatty acids and carbohydrates. By performing these experiments in 
permeabilized myocardial tissue supplied with a fixed amount of substrate (palmitoyl-
carnitine), we have by-passed some of the rate-limiting steps in fatty acid utilization, such as 
sarcolemmal uptake by FAT/CD36 and mitochondrial translocation (CPT-1). By doing so, we 
were able to test the mitochondrial intrinsic ability for fatty acid oxidation. Also, in another set 
of experiments, by providing permeabilized tissue with pyruvate, we were able to test 
mitochondrial oxidation of carbohydrates independent of the insulin-mediated GLUT-4 uptake.  
We found that mitochondrial respiration driven by palmitoyl-carnitine is decreased in DM 
as compared to nonDM, while the pyruvate-driven mitochondrial respiration is unaffected by 
diabetes. This indicates that cardiac mitochondria of diabetic patients have reduced capacity 
for oxidation of long chain fatty acids, while their capacity for carbohydrate oxidation is 
preserved. 
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 There have been findings of altered mitochondrial oxidation of energy substrates were 
previously demonstrated, but the use of atrial tissue from DM2 patients (8,9) and animal 
models of the disease (18). Moreover, even data from a more recent PET study on LV substrate 
metabolism in diabetic patients agrees with our findings by showing that despite increased fatty 
acid esterification and utilization in diabetic myocardium, the percent fatty acid oxidation rate 
is lower (i.e. diabetic heart oxidizes proportionally less of the extracted fatty acids than 
nondiabetic heart) (17).  
Examination of the main factors involved in metabolism of fatty acids and 
carbohydrates (activity and expression of pyruvate dehydrogenase) revealed no difference 
between nonDM and DM patients. These findings suggest that the observed reduction in 
mitochondrial oxidation of palmitoyl in DM myocardium is not a result of metabolic steps 
handling fatty acid intracellular or intramitochondrial uptake (function of FAT/CD36 and 
CPT1, respectively), nor the defects in mitochondrial respiratory chain activity. Rather, these 
findings suggest the main disruption leading to the decreased capacity for fatty acid oxidation 
might be at the level of beta-oxidation.    
In diabetic LV myocardium there is a mismatch between increased fatty acid load to 
the cardiomyocytes and decreased capacity of mitochondria to oxidize their overwhelming 
amounts, causing an accumulation of lipids. Consequently, these conditions could lead to an 
increased accumulation of lipid in form of triglicerides, ceramides and diacyglycerols, which 
can lead to lipotoxic cardiac damage (21).  
Limitations of the present study. Since the current study was performed on human LV 
myocardial tissue obtained during CABG surgery, we were able to obtain only a small size 
biopsy samples, which prevented us from performing all the measurements in tissues from all 
of the patients. Also, both of our patient groups (nonDM and DM) suffered from coronary 
artery disease requiring surgical revascularization.  
Therefore, we were not able to study directly diabetic cardiomyopathy, which is defined 
as myocardial dysfunction in absence of other cardiac risk factors (e.g. CAD, hypertension). 
Furthermore, although there was no obvious difference in severity of CAD between DM and 
nonDM patients, we cannot assess possible differences in microvascular function between the 
two groups. However, both groups of patients had preserved contractile performance, 
suggesting that they were well matched. Moreover, since our findings on reduced oxidation of 
fatty acid in diabetic mitochondria completely agree with previous work performed in human 
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atria of diabetic patients (tissue likely not affected by ischemia) (8, 9), we believe the 
differences observed here are primarily due to diabetes.  
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6. CONCLUSION 
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1. LV myocardium of DM2 patients undergoing CABG surgery has significantly 
altered mitochondrial function 
2. There is a decrease capacity to oxidize long chain fatty acids in the LV 
myocardium mitochondria 
3. Carbohydrate oxidation remains unaffected in LV myocardium mitochondria 
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8. SUMMARY 
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Objectives: The main goal of the present study was to investigate directly the ability of heart 
mitochondria to oxidize fatty acids and carbohydrates in patients suffering from DM2. Since 
DM2 is a metabolic disease which disturbs normal metabolic processes in the entire body, we 
wanted to explore the potential impact on utilization of the main substrates in metabolically 
very active organ, such as heart. Although some studies had been performed in animal models 
of diabetes, investigation conducted on the tissue derived from human DM2 patients enables a 
direct insight into clinically relevant aspects of the disease.  
Patients and Methods: Thirty-seven patients who had been previously diagnosed with 
Coronary Artery Disease (CAD), were hemodynamically stable and were scheduled for 
elective Coronary Artery Bypass Grafting (CABG) surgery. Emergency patients, patients with 
LV ejection fraction (LVEF) below 50%, patients with type 1 diabetes mellitus, concomitant 
valve replacement, and severe renal, hepatic or pulmonary disease were excluded from our 
investigation. The included patients were subdivided into two categories. One group of 
nondiabetic patients (labelled as nonDM group) and the second the diabetic group (labelled 
DM). The diabetic group were patients defined on the clinical diagnosis of Type 2 Diabetes 
(DM2), chronic use of diabetic medication, having a fasting plasma glucose (> 7 mml/L) or a 
glycosylated hemoglobin (HbA1c >6.5%).  Pre, intra- and post-surgical procedures were 
performed according to the standard clinical routines of the Department of Cardiac Surgery. 
This experiment and all subsequent processes follow the Declaration of Helsinki and was 
approved by the Ethical Committees of the University Hospital of Split (2181-147-01). All 
patients were explained the planned procedures and study objectives in detail prior to giving 
the signed informed consent for their enrollment.  
Results: Examination of mitochondrial oxidation of the main energy substrates revealed 
significant alterations in the ability to process fatty acid in DM heart. Upon addition of 
palmitoyl-carnitine, respiration in the presence of ADP was significantly lower in LV 
myocardium from DM patients as compared to nonDM. Cardiac mitochondrial ability to 
oxidize carbohydrates (pyruvate) was not affected in diabetic patients. 
Conclusion:  The study shows that LV myocardium of DM2 patients undergoing CABG 
surgery has significantly altered mitochondrial function, with decreased capacity to oxidize 
long chain fatty acids and unaffected capacity to oxidize carbohydrates.  
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9. CROATIAN SUMMARY 
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Naslov: Metaboličko korištenje slobodnih masnih kiselina i ugljikohidrata u dijabetičkom srcu 
Ciljevi: Glavni cilj ove studije je bio ispitati sposobnost srčanih mitohondrija za oksidaciju 
masnih kiselina i ugljikohidrata kod pacijenata koji boluju od šećerne bolesti tipa 2. Obzirom 
da u toj bolest ujedno dolazi do poremećaja metabolizma u čitavom tijelu, namjera nam je bila 
ispitati njen mogući utjecaj na korištenje energetskih metaboličkih supstrata u metabolički vrlo 
aktivnom organu, poput srca. Iako su ranije napravljene neke slične studije na životinjskim 
modelima dijabetesa, ispitivanje sprovedeno na tkivu ljudskih pacijenata koji boluju od 
dijabetesa tipa 2 omogućuje izravni uvid u klinički relevantni aspekt bolesti. 
Pacijenti i metode: Trideset i sedam pacijenata kojima je ranije dijagnosticirana ishemijska 
bolest srca (CAD), hemodinamski stabilni i na rasporedu za elektivni zahvat postavljanja aorto-
srčane premosnice je bilo uključeno u studiju. Hitni pacijenti, oni s ejekcijskom frakcijom 
lijevog ventrikula ispod 50 %, s dijabetesom tip 1, pratećom zamjenom zaliska i teško 
oštećenom bubrežnom, jetrenom ili plućnom funkcijom su bili isključeni iz istraživanja. 
Uključeni pacijenti su podijeljeni u dvije skupine; pacijenti s dijabetesom tipa 2 (DM) i oni bez 
dijabetesa (nonDM). Dijabetičku su skupinu činili pacijenti s kliničkom dijagnozom dijabetesa 
tipa 2, kroničnom upotrebom antidijabetika, s koncentracijom glukoze natašte višom od 7 
mml/l ili glikoziliranim hemoglobinom višim od 6.6 %. Svi postupci prije, za vrijeme i nakon 
operativnog zahvata su bili provedeni u skladu sa standardnim postupnikom Zavoda za 
kardijalnu kirurgiju. Svi eksperimentalni postupci su bili u sklada s Helsinškom deklaracijom 
i odobreni od strane Etičkog povjerenstva KBC-a Split (2181-147-01). Svim pacijentima je 
detaljno objašnjena planirana  procedura i ciljevi studije prije nego im je dano na izbor 
potpisivanje obrasca informiranog pristanka. 
Rezultati: Ispitivanje mitohondrijske oksidacije glavnih energetskih supstrata je otkrilo 
značajno smanjenu sposobnost srčanog mišića pacijenata s dijabetesom tipa 2 za 
procesuiranjem masnih kiselina. Nakon dodatka palmitoil-karnitina u sustav, mitohondrijska 
respiracija u prisutnosti ADP-a je bila značajno niža u miokardu lijevog ventrikula pacijenata 
s dijabetesom nego onih bez. Istovremeno, sposobnost srčanih mitohondrija za oksidaciju 
ugljikohidrata (piruvata) nije bila smanjena. 
Zaključak: Istraživanje je pokazalo da miokard lijevog ventrikula kod pacijenata s 
dijabetesom tipa 2 koji su podvrgnuti operaciji postavljanja aortokoronarne premosnice ima 
značajno promijenjenu mitohondrijsku funkciju, koja se očituje u smanjenoj sposobnosti za 
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oksidaciju dugolančanih masnih kiselina, uz nepromijenjenu sposobnost za oksidaciju 
ugljikohidrata.  
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